Compare AbbVie Inc (ABBV) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Jones Lang LaSalle Inc — how do they compare? AbbVie Inc trades at $254.02 (market cap $449.91B), while Jones Lang LaSalle Inc trades at $327.46 (market cap $15.43B). The key difference: AbbVie Inc is far larger — about 29.2× Jones Lang LaSalle Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals.
| ABBV | JLL | |
|---|---|---|
Market Cap | $449.91B | $15.43B |
Sector | Health | Real Estate |
52-Week High | $261.07 | $358.66 |
52-Week Low | $184.85 | $248.95 |
Enterprise Value | $513.38B | $18.97B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.76, down 2.42% on the day, with strong technical momentum showing bullish moving averages despite overbought RSI readings. The company demonstrates solid fundamental performance with Q1 2026 earnings beating expectations at $2.65 EPS versus $2.59 expected, continuing a trend of quarterly beats. Revenue growth remains robust at $61.16 billion for 2025, supported by successful portfolio transition beyond Humira patent expiration.
AbbVie presents a compelling investment case with 68% analyst buy ratings and a $266.33 consensus target offering 4.5% upside. Key opportunities include Skyrizi and Rinvoq driving growth, while risks involve patent cliffs in the 2030s and high valuation multiples. The company's dividend aristocrat status and strong cash flow generation support continued shareholder returns.
JLL trades at $332.57, up 1.56% today, with a bullish technical outlook and strong earnings momentum after beating Q1 2026 EPS estimates. Revenue grew to $26.12B in 2025, with net income reaching $792.10M and improving margins. Positive analyst sentiment includes a $405.50 consensus price target, and recent news highlights strategic growth initiatives and inclusion on Zacks Strong Buy lists as of June 2026.
The stock presents a favorable risk-reward profile with a 22% upside to the consensus target, supported by robust cash flow generation and debt reduction. Key risks include economic sensitivity and competitive pressures, but institutional backing and consistent earnings beats underpin a constructive outlook for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
